Enrique Poradosu
Fondateur chez NUVECTIS PHARMA, INC.
Fortune : 10 M $ au 30/04/2024
Profil
Enrique Poradosu is the founder of Nuvectis Pharma, Inc. which is founded in 2020, where he currently holds the title of Executive VP, Chief Scientific & Business Officer.
He held the position of Vice President-Business & Scientific Strategy at Keryx Biopharmaceuticals, Inc. from 2003 to 2016 and Senior VP-Business & Scientific Strategy at Stemline Therapeutics, Inc. from 2016 to 2020.
Dr. Poradosu received his undergraduate and doctorate degrees from The Hebrew University of Jerusalem.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
NUVECTIS PHARMA, INC.
8,47% | 10/05/2024 | 1 504 319 ( 8,47% ) | 10 M $ | 30/04/2024 |
Postes actifs de Enrique Poradosu
| Sociétés | Poste | Début |
|---|---|---|
| NUVECTIS PHARMA, INC. | Fondateur | 27/07/2020 |
Anciens postes connus de Enrique Poradosu
| Sociétés | Poste | Fin |
|---|---|---|
| STEMLINE THERAPEUTICS, INC. | Corporate Officer/Principal | 01/12/2020 |
| KERYX BIOPHARMACEUTICALS | Directeur Technique/Scientifique/R&D | 01/01/2016 |
Formation de Enrique Poradosu
| The Hebrew University of Jerusalem | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| NUVECTIS PHARMA, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Keryx Biopharmaceuticals, Inc.
 Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA. | Health Technology |
Stemline Therapeutics, Inc.
 Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |